Scholarlink

<p>The synergistic combination of two antimicrobial drugs is a promising therapeutic modality for many infectious diseases. However, systemic fungal infections still have a high mortality rate because of distinct in vivo distributions of the two drugs. Here we address this challenge by designing an antifungal polymer that forms micelles suitable for delivering a second antifungal agent to achieve temporal and spatial consistency of delivery. We show that the polymer, which mimics host defense peptides, exerts a synergistic effect with the antifungal amphotericin B (AmB). The AmB-encapsulated micelles (AmBmicelles) greatly reduce the toxicity of AmB through slow release and expand its therapeutic window in vivo. AmBmicelles can selectively target fungal pathogens through charge interactions with the fungal membrane. In mouse models of systemic candidiasis and cryptococcal meningitis, AmBmicelles increase the survival rate by 67–100% compared to the state-of-the-art drug AmBisome or AmBisome and 5-flucytosine combination, suggesting that the strategy may be effective in combating drug-resistant fungal infections including meningitis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effective combinatorial antifungal therapy using a host defense peptide mimic that self-assembles into delivery micelles

  • 期刊论文

  • 发表日期：

    2026年1月2日

查看全文
  • Longqiang Liu,
  • Min Zhou,
  • Ximian Xiao,
  • Zihao Cong,
  • Yueming Wu,
  • Jiayang Xie,
  • Qiang Zhang,
  • Junyu Zhang,
  • Weinan Jiang,
  • Runhui Liu

摘要

The synergistic combination of two antimicrobial drugs is a promising therapeutic modality for many infectious diseases. However, systemic fungal infections still have a high mortality rate because of distinct in vivo distributions of the two drugs. Here we address this challenge by designing an antifungal polymer that forms micelles suitable for delivering a second antifungal agent to achieve temporal and spatial consistency of delivery. We show that the polymer, which mimics host defense peptides, exerts a synergistic effect with the antifungal amphotericin B (AmB). The AmB-encapsulated micelles (AmBmicelles) greatly reduce the toxicity of AmB through slow release and expand its therapeutic window in vivo. AmBmicelles can selectively target fungal pathogens through charge interactions with the fungal membrane. In mouse models of systemic candidiasis and cryptococcal meningitis, AmBmicelles increase the survival rate by 67–100% compared to the state-of-the-art drug AmBisome or AmBisome and 5-flucytosine combination, suggesting that the strategy may be effective in combating drug-resistant fungal infections including meningitis.